Altimmune, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2830 altimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune, Inc.

Altimmune to Host Virtual R&D Day on March 13, 2025 - Mar 6th, 2025 12:30 pm
Altimmune to Participate in the Leerink Global Healthcare Conference - Mar 3rd, 2025 12:30 pm
Altimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Feb 28th, 2025 10:29 am
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - Feb 27th, 2025 12:00 pm
Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors - Feb 25th, 2025 12:30 pm
Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 - Feb 20th, 2025 12:30 pm
With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns - Feb 4th, 2025 10:10 am
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference - Jan 29th, 2025 12:30 pm
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate - Dec 25th, 2024 11:26 am
Altimmune Added to Nasdaq Biotechnology Index - Dec 19th, 2024 12:30 pm
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders - Dec 2nd, 2024 12:30 pm
Altimmune to Participate at Two Upcoming Investor Conferences - Nov 26th, 2024 12:30 pm
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - Nov 15th, 2024 4:00 pm
Altimmune Third Quarter 2024 Earnings: Beats Expectations - Nov 14th, 2024 11:15 am
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update - Nov 12th, 2024 12:00 pm
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 11th, 2024 12:30 pm
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer - Nov 11th, 2024 12:30 pm
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity - Nov 7th, 2024 12:30 pm
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 - Nov 4th, 2024 12:30 pm
Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024 - Oct 15th, 2024 12:00 pm